Voyager Therapeutics, Inc. (VYGR)
Stock Price:
$8.46 USD
0.08 (0.95%)
Updated November 27, 1:00 PM EST - Market closed
Key Info
| Market Cap |
316.96M |
| Revenue (ttm) |
197.27M |
| Net Income (ttm) |
40.09M |
| Shares Out |
37.47M |
| EPS (ttm) |
1.07 |
| PE Ratio |
7.91 |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$8.46 |
| Previous Close |
$8.38 |
| Change ($) |
0.08 |
| Change (%) |
0.95% |
| Day's Open |
8.47 |
| Day's Range |
8.40 - 8.78 |
| Day's Volume |
262,357 |
| 52-Week Range |
6.26 - 15.26 |
More Stats
| Market Cap |
316.96M |
| Enterprise Value |
116.94M |
| Earnings Date (est) |
Mar 17, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
37.47M |
| Float |
24.34M |
| EPS (basic) |
1.07 |
| EPS (diluted) |
1.07 |
| FCF / Share |
-2.95 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
12.65% |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.21M |
| Short Ratio |
5.10 |
| Short % of Float |
4.97% |
| Beta |
1.78 |
| PE Ratio |
7.91 |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
1.61 |
| PB Ratio |
1.90 |
| Revenue |
197.27M |
| Operating Income |
37.35M |
| Net Income |
40.09M |
| Free Cash Flow |
-109.98M |
| Net Cash |
200.02M |
| Net Cash / Share |
5.34 |
| Gross Margin |
-7.78% |
| Operating Margin |
18.93% |
| Profit Margin |
20.30% |
| FCF Margin |
-55.75% |
| ROA |
7.23% |
| ROE |
29.22% |
| ROIC |
36.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (13)
| Buy |
6 |
| Overweight |
2 |
| Hold |
5 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$15.33*
(81.21% upside)
Low
10.0
Current: $8.46
High
21.0
Target: 15.33
*Average 12-month price target from 12 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 104 | 7.62 | 10.14 | 14.22 | 17.33 | - |
| Revenue Growth | 1270.14% | -24.82% | -28.73% | -17.96% | - | - |
| Gross Profit | 104 | 7.62 | 10.14 | 14.22 | 17.33 | - |
| Operating Income | -51.68 | -91.10 | -71.86 | -41.30 | -20.25 | -14.37 |
| Net Income | -43.60 | -88.29 | -70.70 | -40.19 | -29.67 | -16.32 |
| Shares Outstanding | 35.90 | 32.07 | 26.80 | 25.30 | 4.19 | 0.64 |
| Earnings Per Share | -1.21 | -2.75 | -2.64 | -1.59 | -9.14 | -27.83 |
| Operating Cash Flow | 48.67 | -15.89 | -61.35 | -42.48 | 41.30 | -11.92 |
| Capital Expenditures | -7.55 | -4.31 | -3.99 | -5.03 | -1.03 | -2.99 |
| Free Cash Flow | 41.12 | -20.19 | -65.34 | -47.51 | 40.27 | -14.91 |
| Cash & Equivalents | 282 | 156 | 169 | 174 | 194 | 7.04 |
| Net Cash / Debt | 282 | 156 | 169 | 174 | 194 | 7.04 |
| Assets | 355 | 177 | 184 | 190 | 229 | 11.50 |
| Liabilities | 255 | 131 | 50.43 | 53.64 | 60.38 | 10.35 |
| Book Value | 99.51 | 46.45 | 134 | 136 | 169 | -20.83 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Voyager Therapeutics, Inc. |
| Country |
United States |
| Employees |
185 |
| CEO |
G. Andre Turenne |
Stock Information
| Ticker Symbol |
VYGR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: VYGR |
| IPO Date |
November 11, 2015 |
Description
Voyager Therapeutics, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and alpha-synuclein program for synucleinopathies, Parkinson's disease, Lewy Body Dementia, and multiple system atrophy. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.